Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.
Jaeger U, Tam CS, Borchmann P, McGuirk JP, Johansen M, Waller EK, Jaglowski S, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Salles G, Schuster SJ, He F, Maziarz RT, Mayer S, Makita S, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Goto H, Colicino S, Agarwal A, Lobetti-Bodoni C, Bishop MR.
Jaeger U, et al. Among authors: lobetti bodoni c.
Blood Adv. 2022 Aug 23;6(16):4816-4820. doi: 10.1182/bloodadvances.2021006193.
Blood Adv. 2022.
PMID: 35687492
Free PMC article.
No abstract available.